Belantamab mafodotin with bortezomib and dexamethasone for previously treated relapsed/refractory multiple myeloma

Belantamab mafodotin is in clinical development in combination with bortezomib and dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM) in adult patients who have previously received at least one prior therapy. MM is a rare form of cancer characterised by excessive production (proliferation) and improper function of certain cells (plasma cells) found in the bone marrow. Myeloma develops due to DNA changes during the development of the plasma cell, producing an abnormal cell that begins to proliferate and produce more cancerous cells. Patients with MM often go through many cycles of treatment options to improve overall survival, which can sometimes lead to poor survival outcomes for patients whose disease has become resistant to the currently available therapy options.